St. Jude Children’s Research Hospital is one of the world’s premier research and treatment centers for childhood cancer. With unique clinical trials, innovative science and comprehensive patient care, our physicians and researchers are defining new frontiers in pediatric oncology.
Treatment Information
Meet Our Patients
We treat the toughest cases.
-
von Hippel-Lindau: Focusing on an Invisible Foe
As a von Hippel-Lindau Clinical Care Center, St. Jude can focus the treatment experience for families affected by the rare genetic disorder.
-
Cancer Predisposition: Power through the PCGP
As a result of the Pediatric Cancer Genome Project, families facing an increased risk of inherited cancers can turn to the St. Jude Cancer Predisposition Program.
-
Overcoming the Odds of Familial Monosomy 7
Researchers make discoveries about a rare bone marrow disorder called familial monosomy 7 syndrome.
-
Field of Genes: Hispanic Children and ALL
Researcher discovers why Hispanic children have a higher risk of developing leukemia and relapsing.
-
A Cancer Chameleon: Mixed-phenotype Acute Leukemia
Features of mixed-phenotype acute leukemia can change, enough to switch the diagnosis from one acute leukemia to the other.
-
Spurred into Action: Discovering the Origins of Rhabdomyosarcoma
In the race to increase survival rates for the soft-tissue cancer, one researcher proved rhabdomyosarcoma can originate in the inner surface of blood vessels.
Comprehensive Cancer Center
St. Jude is the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children.
St. Jude Cloud
St. Jude Cloud offers the world's largest public repository of pediatric cancer genomics data alongside unique analysis and visualization tools.
Innovative Clinical Trials
St. Jude develops more oncology clinical trials than any other U.S. children's hospital. Armed with leading-edge research, superb resources, and a strongly collaborative culture, we translate laboratory discoveries into new options for children with tough-to-treat cancers.
Pediatric Cancer Genome Project
The roots of pediatric cancer are hidden deep within a child’s DNA. The St. Jude—Washington University Pediatric Cancer Genome Project is the world’s most ambitious effort to discover the origins of childhood cancer and seek new cures.
Cancer Survivorship Research
Improved treatments for childhood cancer have helped swell the ranks of survivors to more than 425,000 individuals nationwide. St. Jude is pioneering the field of cancer survivorship with major research programs that follow thousands of survivors for decades after their treatment.
Latest Oncology Research
-
Understanding how brain tumor treatment affects the brain
An unprecedented study finds that survivors of childhood brain tumors are at risk of memory and intelligence deficits. A key goal? Catch them early.
-
Child life specialists help young patients get ready for radiation treatment
Child life specialists show support interventions decrease sedation use and cost for radiation therapy.
-
Finding new ways to protect patients during chemo
Newly identified type of lung macrophage protects chemotherapy-treated mice from lethal bacterial pneumonia despite absence of neutrophils.
-
Where a brain tumor begins
Research led by a St. Jude scientist has pinpointed likely cells of origin for a common childhood brain tumor, Group 4 medulloblastoma.
-
Clues to how aggressive sarcomas beat chemotherapy drugs
Enzyme linked to neurodegenerative disorders may play a reversible role in enhancing the aggressiveness of sarcoma tumors.
-
Advances in saving lives and sight
Incorporating topotecan into front-line therapy of advanced localized retinoblastoma cures patients and improves survival of eyes with useful vision.
-
Measuring response to leukemia treatment may save more lives
Measuring treatment response proves to be a powerful tool for guiding leukemia therapy.
-
Clues to precision treatments for a tough childhood leukemia
Researchers reveal genetic secrets of a high-risk pediatric leukemia called Ph-ALL, and find treatment potential in the drug ruxolitinib.
-
Preserving the power of glucocorticoids to fight leukemia
Researchers led by St. Jude scientists have identified a mechanism that helps leukemia cells resist glucocorticoids, a finding that lays the foundation for more effective treatment of cancer and possibly a host of autoimmune diseases.
-
Biostatisticians build a better analytic tool
Researchers craft a new approach for mining genomic data for rare genetic variations that may play a role in disease risk.
-
Applied math and supercomputing help smooth transition from lab to clinic
A modeling approach used lab data to find the optimal drug dose in a successful clinical trial for children with recurrent ependymoma.
-
Surprising number of young cancer patients are predisposed to the disease
Landmark study shows almost one in 10 children with cancer were born with an increased genetic risk for the disease.
-
Targeted therapy stalls or shrinks tumors in some medulloblastoma patients
A new era of personalized medicine has begun for some patients with the brain tumor medulloblastoma.
-
Genome reveals clues for better diagnosis and treatment of rare adrenal cancer
St. Jude scientists identify key molecular events in pediatric adrenocortical tumors. The findings could help clinicians identify most malignant subtypes and lead to better treatment.
-
Genetic change reveals precision medicine possibilities for a high-risk leukemia
A possible targeted therapy is found for a high-risk form of acute lymphoblastic leukemia, the most common childhood cancer.